Aviceda Therapeutics
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Aviceda Therapeutics firmographics
Firmographics- Name
- Aviceda Therapeutics
- Legal name
- Aviceda Therapeutics, Inc.
- Website
- https://avicedarx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Aviceda Therapeutics industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
- akta.pro secondary industries
- RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where Aviceda Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aviceda Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical stage biotech company. Revenue will come from commercialization of AVD-104 and other pipeline candidates upon FDA approval. AVD-104 is being developed for geographic atrophy (GA) secondary to AMD as lead indication, with expansion into diabetic macular edema (DME), uveitis, and retinal degenerative diseases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Aviceda Therapeutics product offering
Product offeringCore offering
Aviceda Therapeutics is a clinical-stage biotech company developing glyco-immune checkpoint therapeutics through its proprietary HALOS (High-Affinity Ligands of Siglecs) nanotechnology platform. The company's lead product candidate is AVD-104, a sialic acid-coated nanoparticle designed as a first-in-class glyco-immune checkpoint modulator to slow the progression of geographic atrophy secondary to dry age-related macular degeneration, with additional pipeline programs for diabetic macular edema, uveitis, retinal degenerative diseases, and pulmonary indications.
Product overview
Aviceda Therapeutics is a clinical-stage biotech company developing glyco-immune checkpoint therapeutics through its proprietary HALOS™ (High-Affinity Ligands of Siglecs) nanotechnology platform. The company's lead product is AVD-104, a sialic acid decorated nanoparticle that serves as a first-in-class glyco-immune checkpoint modulator for treating geographic atrophy (GA) secondary to dry age-related macular degeneration. The company is also developing additional pipeline candidates including Siglec Targeting Ligands for pulmonary disease, and has ongoing research in CNS and oncology. AVD-104 is currently in Phase 2b/3 clinical trials for geographic atrophy, with additional Phase 2 trials for diabetic macular edema and uveitis.
Differentiator
Problem solved
Functional benefit
Products and services
- AVD-104 AVD-104 is a sialic acid-coated nanoparticle and first-in-class glyco-immune checkpoint modulator administered by intravitreal injection for slowing the progression of geographic atrophy secondary to dry age-related macular degeneration. It acts as a Siglec checkpoint modulator to suppress activation of macrophages, microglia, and monocytes.
- Siglec Targeting Ligand (Pulmonary) A Siglec targeting ligand being developed for pulmonary disease indications as part of Aviceda's broader pipeline expansion beyond ophthalmology using the HALOS nanotechnology platform.
Quantifiable outcome
- AVD-104 reduced GA lesion growth by 31-38% compared to prior randomized placebo-controlled trials or natural history cohorts
- +4 more outcomes
Companies that use Aviceda Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Aviceda Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aviceda Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Queen's University Belfast (QUB)coreAviceda partnered with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen's University Belfast to spearhead development of the next generation of glyco-immune therapeutics. This strategic partnership supports the advancement of the HALOS technology platform.
- University of GeorgiacoreAviceda partnered with world-renowned glyco-chemist Prof. Geert-Jan Boons and analytical glyco-biologist Dr. Parastoo Azadi and their teams at Complex Carbohydrate Research Center (CCRC) to spearhead development of the next generation of glyco-immune therapeutics.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Aviceda Therapeutics competitors and assessment
Company assessmentDirect peers
- Apellis Pharmaceuticals: Apellis developed and commercializes Syfovre (pegcetacoplan), the first FDA-approved treatment for geographic atrophy secondary to AMD. It is the most direct competitor to Aviceda's AVD-104 in the same indication and patient population.
- Iveric Bio (Astellas): Iveric Bio developed Izervay (avacincaptad pegol), another FDA-approved complement inhibitor for geographic atrophy, and was acquired by Astellas for $5.9B in 2023. It is a direct competitor to Aviceda in GA and serves as a comparable exit reference.
- Annexon Biosciences: Annexon is a clinical-stage complement-focused biotech developing therapeutics for retinal and neurodegenerative diseases. It is comparable to Aviceda as a clinical-stage immunology-modulating biotech targeting ophthalmology indications.
- Oyster Point Pharma (Viatris): Oyster Point Pharma was an ophthalmology-focused biotech acquired by Viatris in 2023 for its dry eye therapy TYRVAYA. It is directly comparable to Aviceda given shared leadership (CEO Jeffrey Nau led Oyster Point's IPO and Viatris acquisition) and overlapping ophthalmology commercial pathways.
Emerging players
- Gemini Therapeutics (now Disc Medicine successor entities): Gemini Therapeutics was a clinical-stage biotech developing therapeutics for age-related macular degeneration and geographic atrophy. It is comparable to Aviceda as a small-cap clinical biotech focused on dry AMD/GA with novel mechanisms.
- REGENXBIO: REGENXBIO is a clinical-to-commercial gene therapy biotech with ophthalmology programs including ABBV-RGX-314 for wet AMD. It is comparable to Aviceda as a late-stage retinal disease biotech pursuing novel modalities.
- Adverum Biotechnologies: Adverum is a clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD and diabetic macular edema. It is comparable to Aviceda as a clinical-stage ophthalmology biotech targeting retinal disease indications.
- Kodiak Sciences: Kodiak Sciences is a clinical-stage biotech developing antibody-based therapeutics for retinal vascular diseases including DME and AMD. It is comparable to Aviceda as a late-stage clinical ophthalmology biotech with a novel therapeutic platform.
- Graybug Vision: Graybug Vision (now Rectify Pharmaceuticals) was a clinical-stage ophthalmology biotech developing sustained-release therapeutics for retinal diseases including GA. It is comparable to Aviceda as a small clinical biotech targeting GA with a differentiated delivery approach.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics is a clinical-stage cell therapy company with an ophthalmology program (OpRegen for geographic atrophy). It is comparable to Aviceda as a clinical-stage biotech pursuing novel modality approaches to GA and retinal disease.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Aviceda Therapeutics social profiles
Digital presenceAviceda Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aviceda Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Aviceda Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aviceda Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aviceda Therapeutics
What does Aviceda Therapeutics do?
Aviceda Therapeutics is a clinical-stage biotech company developing glyco-immune checkpoint therapeutics through its proprietary HALOS (High-Affinity Ligands of Siglecs) nanotechnology platform. The company's lead product candidate is AVD-104, a sialic acid-coated nanoparticle designed as a first-in-class glyco-immune checkpoint modulator to slow the progression of geographic atrophy secondary to dry age-related macular degeneration, with additional pipeline programs for diabetic macular edema, uveitis, retinal degenerative diseases, and pulmonary indications.
Is Aviceda Therapeutics a public or private company?
Aviceda Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aviceda Therapeutics founded?
Aviceda Therapeutics was founded in 2018. It employs 51 to 100 people.
Where is Aviceda Therapeutics based?
Aviceda Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Aviceda Therapeutics make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Aviceda Therapeutics's main competitors?
Direct peers on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), Annexon Biosciences and Oyster Point Pharma (Viatris). Emerging players are Gemini Therapeutics (now Disc Medicine successor entities), REGENXBIO, Adverum Biotechnologies, Kodiak Sciences, Graybug Vision and Lineage Cell Therapeutics.
Does Aviceda Therapeutics have an API?
No public API is recorded for Aviceda Therapeutics.
What industry is Aviceda Therapeutics in?
Aviceda Therapeutics's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAI, RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target). Its NAICS code is 325414 and its SIC code is 2834.